
ã¿ã³ãã¯è³ªããŒã¹ã®ã¯ã¯ãã³ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãéºäŒåããŒã¹ã®ã¯ã¯ãã³ãçæãããã®ãšã¯èããç°ãªã
ãã¿ã³ãã¯è³ªããŒã¹ã®ã¯ã¯ãã³ãšéºäŒåããŒã¹ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ã¯ãã³ã®éãã«ã€ããŠã§ããã¡ãã£ã¢ã§ã¯æ··åã誀éåãããŠå ±éãããŠããŸãã
å°éå®¶ãæããããšèããæ¥çš®åŸã®ç±ãäœèª¿äžè¯ãæ¥æ¬äººã¯ã¯ã¯ãã³ãå¹ããŠãããšåãã§ããããŸããããã ãã§ãã¡ãã£ã¢ã®çœªã¯éãð¡
ðã¯ã¯ãã³éçºè
ã§ããåãªãŒã¹ãã©ãªã¢å·ããªã³ããŒã¹å€§åŠã®
ãã³ã©ã€ã»ããããã¹ããŒææð圌ã®ããŒã ã¯ãã³ãããã¯ã®æ©ã段éã§ããŸããŸãªãã©ãããã©ãŒã æè¡ã調æ»ããâ mRNA âã¯ã¯ãã³ãé²ããããšã«å察ã
âŽmRNAãæçæã®æºåãã§ããŠãããšã¯æããªãã£ããã¯ã¯ãã³ã®å°éå®¶ã¯ãé·æçãªå®å šæ§ããŒã¿ããªããããèŠå¶åœå±ã®æ¿èªãåŸãããšã¯æ±ºããŠãªããšèããŠãããããã¯çæ°ã®æ²æ±°ã ã
âµåæã®ç¬¬IçžããŒã¿ãèŠããšã15ã20ïŒ ã®äººãé«ç±ãåºããæå€§ã§1é±éãäœèª¿ã厩ããªã©ãåå¿åæ§ãæãããã£ãã
ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿ð¿
ð§COVID-19ã¯ã¯ãã³ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ "æ¯ "ãªã®ãïŒ2022幎2æ15æ¥
ããªã¢ã³ãã»ããã·å士è
SARS-CoV-2ãŠã€ã«ã¹ã®è¡šé¢ã«ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãCOVID-19ã®ç åæ§ã«é¢äžããŠããã
ããããã¯ã¯ãã³æ¥çš®åŸã®äœå ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ "æ¯ "ã§ããããšãæžå¿µãããŠããã
ããããæžå¿µãææããããã«ãã¯ã¯ãã³éçºè ã§ããåãªãŒã¹ãã©ãªã¢å·ããªã³ããŒã¹å€§åŠã®ãã³ã©ã€ã»ããããã¹ããŒææã«è©±ãèããã圌ã¯ãCOVAX-19ïŒãŸãã¯SpikogenïŒãšããã¿ã³ãã¯è³ªããŒã¹ã®ã¯ã¯ãã³ãéçºããã€ã©ã³ã§ç·æ¥äœ¿çšã®èªå¯ãåããŠããã
圌ã«ãããšã#ã¿ã³ãã¯è³ªããŒã¹ã®ã¯ã¯ãã³ïŒNovavax/COVAX-19ïŒã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ã#éºäŒåããŒã¹ã®ã¯ã¯ãã³ãïŒPfizer/Moderna/AZïŒãçæãããã®ãšã¯èããç°ãªããšã®ããšã ã
ð¿ã¹ãã€ã¯ãããã€ã³ã¯ "æ¯ "ãªã®ãïŒ
ããããã¹ããŒææ:
ãç§èªèº«ãã¹ãã€ã¯ãããã€ã³ã»ã¯ã¯ãã³ãäœåºŠãæ¥çš®ããçµéšããããŸãããæ¬è³ªçãªæ¯æ§ã¯ãªããšèããŠããŸããç 究宀ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãããã®çްèã«ä»çããããšããã现èã¯æ»æ» ããäœãããããªããšã¯ããŸããã§ããããããæ¬åœã®æ¯çŽ ã现èã«ã€ãããã现èã¯ããã«æ»ãã§ããŸãããã¹ãã€ã¯ã»ãããã€ã³ã«ã¯ãæã ãèŠãããšã®ã§ããæãããªãæ¯çŽ ãã®äœçšã¯ãªããã
ãããã«æäžããåã«ãããŠã¹ã«æ¥µããŠå€§éã«æ³šå°ããŸããããå¯äœçšã¯èŠãããŸããã§ãããããã¯éåžžã«å¿åŒ·ãããšã§ãããç Žå·é¢šæ¯çŽ ã®ãããªæ¬ç©ã®æ¯çŽ ã¯ã極埮éã§ãèŽæ»éã«ãªããŸããã ãããã¹ãã€ã¯èçœã¯æ¬åœã®æå³ã§ã®æ¯çŽ ã§ãªãããšã¯æããã§ããå®éã粟補ããã¹ãã€ã¯ã»ãããã€ã³ã泚å°ããŠãçç©åŠçã«ã¯ãäžæŽ»æ§ãã§ããããã®ããã«ãã¢ãžã¥ãã³ããã䜵çšããªããã°ãªããªãã®ã§ãã
ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãããŠã¹ã«æ³šå°ããŠãã匷ãå ç«åå¿ã¯åŸããããå ç«ç³»ã«ã»ãšãã©ç¡èŠãããŠããŸãã®ã§ããããã§ãã¹ãã€ã¯ã¿ã³ãã¯ã«ç³ããŒã¹ã®ã¢ãžã¥ãã³ããå ããå ç«ç³»ãã¹ãã€ã¯ã¿ã³ãã¯ã«å¯ŸããŠé²åŸ¡æäœãT现èãäœã£ãŠåå¿ããããã«ããã®ã§ãã ããããã¿ã³ãã¯è³ªãäž»æåãšããã¯ã¯ãã³ãäžè¬çã«å®å šã§ããçç±ã§ããäœã¯ã»ãšãã©ã®ã¿ã³ãã¯è³ªã«çŽé¢ãããšããããšã倿¥ã®ãã®ã§ãã£ãŠããç¡å®³ãšã¿ãªããŠãããã«åå¿ããŠæäœãäœãåªåãããŸããããããã倿¥ã¿ã³ãã¯è³ªãã¢ããé žã®éšåã«ãŸã§ä»£è¬ããŠããŸãããšãå€ãã®ã§ããã
ð¿ããããéºäŒåããŒã¹ã®ã¯ã¯ãã³ã«ã€ããŠã¯ã©ãã§ããããããããã®ã¯ã¯ãã³ã«ãã£ãŠçæãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãå ç«ç³»ã«ç°ãªã圱é¿ãäžããã®ã§ããããïŒ
ã¿ã³ãã¯è³ªããŒã¹ã®ã¯ã¯ãã³ã¯ãäžå®éã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãçèå ã«æ³šå°ãã现èå€ã«æ®ãã
粟補ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ã泚å°éšäœã§çè现èå ã«å ¥ã蟌ãŸãã现èå€ã«çãŸãã
ã现èå€ã«çãŸã£ãã¿ã³ãã¯è³ªã¯ãã¡ã¢ãªãŒB现èïŒãã©ãºã现èã«å€åããïŒã«æç€ºãããæäœãã€ããå§ããã®ã§ããããã¯ããã¡ãŒãžãšåŒã°ããç¹æ®ãªçްèã¯ãå ç«ç³»ã®ãŽãç®±ã§ããã现èå€ã®ãã¹ãŠã®ã¿ã³ãã¯è³ªãäžæããåè§£ããŸãããããã£ãŠãä»ã®çްèã®äžã«å ¥ã蟌ãããšã¯ãªãã®ã§ãæ¯æ§ã¯ã»ãšãã©ãªãã§ããããããšããããã¹ããŒææã¯èšãã
ããã¯ããã¡ãŒãžã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªããã¡ãŽãœãŒã ãšåŒã°ããå°ããªãŽãè¢ã®äžã«å ¥ããŠé£ã¹ãŠããŸãã®ã§ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã现èã®äžã§èªç±ã«åãåãããšãã§ããã现èã®æ©èœãé»å®³ããŠããŸãã®ã§ããããšãããããã¹ããŒææã¯ä»ãå ããã
ðððããããå
ãéºäŒåããŒã¹ðððéã«ãéºäŒåããŒã¹ã®ã¯ã¯ãã³ãã现èãçæããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãå ç«ç³»ãšã®çžäºäœçšãå šãç°ãªãã
éºäŒåããŒã¹ã®ã¯ã¯ãã³ã¯ãç¹æ®ãªå ç«çްèã ãã§ãªããå šèº«ã®çްèå ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãç¡å¶éã«è£œé ããããšã«ãªãã
mRNAååã¯ã现èå ã§ããå®å®ã«ãªãããã«æå³çã«æäœãããŠãããããœã€ããŠãªãžã³ãååãmRNAã«ä»å ããéåžžã®mRNAãããåæžæãé·ãããŠããã®ã ããã®ããã现èå ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çç£ã¯åæ¢ããŠããªãããã®ããšã®æå³ãããšããã¯ãããåãã£ãŠããªãã
Cellèªã«æ²èŒãããæè¿ã®ç ç©¶ã§ã¯ãã¯ã¯ãã³ç±æ¥ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšmRNAãããªã³ãç¯ã®èäžå¿ã§æé·2ã«æéæç¶ããããšã瀺ãããŠããã
mRNAã¯çްèã®æ žã«å ¥ãããDNAãšçžäºäœçšããªããšèšãããŠããããããããã¹ããŒææã¯ã现èå ã§è£œé ãããŠããã¹ãã€ã¯ã»ã¿ã³ãã¯è³ªãçŽ°èæ©èœã«åœ±é¿ãäžããã®ã§ã¯ãªãããšæžå¿µããŠããã
ãéºäŒåã¯ã¯ãã³ ã§ã¯ã现èå ïŒçްè質å ïŒã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªã補é ããŠãããäœãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®éã¯æªç¥æ°ã§ãããã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãæ£åžžãªçŽ°èæ©èœãé»å®³ããå¯èœæ§ãããããŸãæ žã«ç§»è¡ããå¯èœæ§ããããŸããçµå±ãããã¯ãŠã€ã«ã¹èªèº«ãè¡ãããšã§ãçŽ°èæ©æ§ã®ä¹ã£åãã®äžç°ãšããŠãã¹ãã€ã¯ã¿ã³ãã¯è³ªã现èå ã§çºçŸããããšããããšãªã®ã§ããããšè¿°ã¹ãã
ãã®è«æãè£ä»ããããã«ãç ç©¶è ãã¡ã¯ãå®éšå®€ã®çŽ°èæ ªãçšããŠãã¹ãã€ã¯ã¿ã³ãã¯è³ªã "DNAæå·ä¿®åŸ©ãèããé»å®³ãã "ããšã瀺ãç ç©¶çµæãçºè¡šããŠããã
ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãã€ã³ã¿ãŒãã§ãã³ãªã©ã®éèŠãªæãŠã€ã«ã¹é²åŸ¡ãé»å®³ãããªã©ãçŽ°èæ©èœãé»å®³ããå¯èœæ§ãããããšã«å ãããã®çްèã®è¡šé¢ã«æç€ºããããã©ãŒT现èã«èªèãããŠæ»æãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãçºçŸãã现èãæ»ã«è³ããããå¯èœæ§ããããŸããããšãããããã¹ããŒææã¯è¿°ã¹ãŠããã
å®éãã¹ãã€ã¯èçœã¯çްèããææ³ãããè¡æ¶²ã®äžã«å ¥ã蟌ãããšãã§ãããããå°èŠæš¡ãªç ç©¶ã§ã¯ãã¢ããã®mRNAã¯ã¯ãã³ã®æ¥çš®åŸã13人ã®åå è ã®ãã¡11人ã®è¡æ¶²äžã«ã¹ãã€ã¯ã¿ã³ãã¯ãæ€åºãããããšã瀺ãããŠããã
æãæžå¿µãããã®ã¯ããã¡ã€ã¶ãŒç€Ÿèªèº«ã®çäœå ååžç ç©¶ã®èŠå¶ããŒã¿ã§ãããïŒè¡šåç §ïŒ

ãã®ããŒã¿ã¯ãmRNA-è質ããç²åããæåã«ææ¡ãããããã«æ³šå ¥éšäœã«å±æçã«ãšã©ãŸãã®ã§ã¯ãªãã埪ç°ããŠæ§ã ãªçµç¹ãèåšã«æ²çããããšã瀺ããŠããã
åç©å®éšã§ã¯ãmRNA-è質ããç²åã¯å¯è ãèèãåµå·£ãèŸèã«æ²çããããšãåãã£ãŠããããŸããè質ãšã®çžæ§ãè¯ãã®ã§ãè¡æ¶²è³é¢éãééããŠè³ã«æ²çããå¯èœæ§ããããããããã¹ããŒææã¯ãã®ç¹ãæžå¿µããŠããã
ã¿ã³ãã¯è³ªããŒã¹ã®ã¯ã¯ãã³ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®å Žåãã¿ã³ãã¯è³ªã倧ããããŠè¡æ¶²è³é¢éãééã§ããªãããããã®ãããªããšã¯èµ·ããããªãã
mRNA-è質ããç²åã®åèåšãžã®èç©ã®é·æçãªæçŸ©ãç¹ã«ããŒã¹ã¿ãŒãç¹°ãè¿ããåŸã®æçŸ©ã¯ããŸã äžæã§ããã
ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·ð·
ð¶QAJFããŒã ããŒãžð¶
ïŒççž® URL http://bit.ly/3QzjIQF ïŒ